A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors

Launched by CSPC MEGALITH BIOPHARMACEUTICAL CO.,LTD. · May 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called SYS6040, which is given as an injection, for patients with advanced solid tumors, including small cell lung cancer. This is the first time this treatment is being tested in humans, and the main goals are to see how safe it is, how well it is tolerated, and if it shows any promise in treating these types of cancers. The study is currently looking for participants aged 18 and older who have solid tumors that have not responded to standard treatments or have no other treatment options available.

To be eligible for the trial, participants must have a confirmed diagnosis of advanced solid tumors and measurable disease. They should also be in relatively good health, with a life expectancy of at least three months. However, there are specific health criteria that must be met, such as certain blood counts and organ function levels. Participants can expect to receive the SYS6040 treatment and will be closely monitored for any side effects or responses to the treatment. It’s important for potential participants to understand the study procedures and sign an informed consent form before joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1）Aged ≥18 years; 2) Subjects with histologically or cytologically confirmed advanced solid tumors who have failed standard therapy, are intolerant to standard therapy, or have no options of standard of care. During cohort expansion, subjects will be enrolled as follows: Cohort 1: SCLC subjects who failed or were intolerant to at least one prior platinum-containing chemotherapy regimen; Cohort 2: Subjects with DLL3-positive malignant solid tumors who failed standard therapy, are intolerant to standard therapy, or have no options of standard of care.
• 3) At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST v1.1); 4) ECOG score of 0 or 1; 5) Life expectancy ≥3 months; 6) Laboratory parameters meeting the following criteria:
• • 1. Neutrophil count ≥1.5×109/L;
• • 2. Platelet count ≥100×109/L;
• • 3. Hemoglobin ≥9 g/dL;
• • 4. Total bilirubin ≤1.5×ULN, ALT and AST ≤2.5×ULN (In cases with liver metastases: total bilirubin ≤3×ULN and ALT/AST ≤5×ULN);
• • 5. Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min;
• • 6. International Standardized Ratio (INR) or activated partial thromboplastin time (APTT) ≤1.5×ULN.
• • a. Fertile males and females must use reliable contraception throughout the study period and for 9 months after the last dose. Females aged 18-60 years must have negative blood pregnancy results within 7 days before the first dose.
• • 7) Understand and voluntarily sign the informed consent form (ICF).
• Exclusion Criteria:
• 1. Having received systemic antitumor therapy within 4 weeks before first dose, including: Chemotherapy, macromolecular targeted therapy, antiangiogenic therapy, biotherapy, immunotherapy, radiotherapy (except palliative radiotherapy for bone metastasis pain relief), except:
• • 1. Oral fluorouracil agents and small molecule targeted drugs within 2 weeks before first dose or within 5 half-lives (whichever is longer);
• • 2. Traditional Chinese medicines with antitumor indications within 2 weeks before first dose.
• • 2. Used or required to use strong CYP3A4 inhibitors/inducers within 2 weeks before first dose or during the study;
• • 3. Previous treatment with antibody-drug conjugates (ADCs) containing topoisomerase I inhibitors as payload;
• • 4. Having received systemic corticosteroid therapy (\>10 mg prednisone equivalent daily for \>7 days) or other immunosuppressants within 2 weeks before treatment initiation (inhaled/topical steroids or adrenal replacement therapy \>10 mg prednisone equivalent permitted without active autoimmune disease);
• • 5. Having received transfusion, EPO, TPO, IL-11, G-CSF or GM-CSF therapy within 2 weeks before first dose;
• • 6. Having used or required to use QT-prolonging/shortening drugs within 7 days before first dose or during C-QTc study period, or have risk factors for QT prolongation/arrhythmia (e.g., heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death in first-degree relatives \<40 years);
• • 7. Severe cardiovascular/cerebrovascular disease history；
• • 8. History of other primary malignancies (except cured localized tumors like basal cell carcinoma, squamous cell carcinoma of skin, superficial bladder cancer, carcinoma in situ of prostate/cervix/breast, or subjects with other primary tumors showing no recurrence for ≥5 years);
• • 9. Clinically confirmed active pneumonia at screening or history of interstitial lung disease;
• • 10. Uncontrolled serous effusions requiring frequent drainage or medical intervention at screening (e.g., pleural/peritoneal/pericardial effusions needing additional intervention within 2 weeks after initial treatment, excluding cytological examination);
• • 11. Brain metastases or spinal cord compression at screening (except those completing local therapy with ≥4-week steroid discontinuation and stable imaging/neurological symptoms for ≥4 weeks before treatment initiation);
• • 12. Severe unhealed wounds/ulcers/fractures, or major surgery within 4 weeks before first dose, or planned elective surgery during study;
• • 13. Clinically confirmed active HBV or HCV.Active HBV definition: HBcAb or HBsAg positive with HBV DNA above ULN; Active HCV definition: HCV antibody positive with HCV RNA above ULN;
• • 14. Active tuberculosis confirmed clinically, or TP-Ab positive, or HIV-Ab positive, or history of immunodeficiency diseases/organ transplantation/allogeneic hematopoietic stem cell transplantation;
• • 15. Significant bleeding tendency within 4 weeks before first dose, investigator-assessed high-risk of gastrointestinal hemorrhage/hemoptysis, or congenital bleeding disorders/coagulopathy;
• • 16. Active infection requiring medication or unexplained fever ≥38.5°C during screening;
• • 17. History of psychotropic substance abuse, alcoholism, or drug addiction;
• • 18. Pregnancy or lactation at screening;
• • 19. Persistent adverse reactions from prior antitumor therapy not recovered to CTCAE v5.0 ≤Grade 1 or baseline (except alopecia/nail changes/other investigator-deemed non-safety concerns);
• • 20. Investigator-determined ineligibility for study participation.